Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit
Media Partnership
Between Immune Discovery and Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit
As the first industry-led forum dedicated to transforming the Myasthenia Gravis (MG), CIDP, GBS and MMN treatment landscapes, the Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit (July 21-23, 2026 | Boston, MA) will bring together leading biopharma experts to tackle the mechanistic and translational challenges shaping this rapidly evolving space.
This event will unite 65+ end-to-end biotech and pharma professionals to strengthen translational research and address key challenges in disease biology, patient stratification, and biomarker validation. Attendees will explore the evolving landscape of FcRn inhibition, complement targeting, and B-cell modulation through expert-led presentations, panel discussions, and dedicated workshops.
Unlike pathway-specific or clinician-led events, this summit is indication-focused, mechanism-driven and tailored exclusively to drug developers, enabling deeper discussion on pathophysiology, differentiation and translational strategy.
Join your peers this July to de-risk development, identify new opportunities and gain a competitive edge in one of the fastest-moving areas of immunology and neurology.
URL - https://autoimmune-neuromuscular-drugdevelopment.com/?utm_source=immune-discovery&utm_medium=media-partner&utm_campaign=web-visitors&utm_content=companies-attending%2Fev-71061
Between Immune Discovery and Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit
As the first industry-led forum dedicated to transforming the Myasthenia Gravis (MG), CIDP, GBS and MMN treatment landscapes, the Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit (July 21-23, 2026 | Boston, MA) will bring together leading biopharma experts to tackle the mechanistic and translational challenges shaping this rapidly evolving space.
This event will unite 65+ end-to-end biotech and pharma professionals to strengthen translational research and address key challenges in disease biology, patient stratification, and biomarker validation. Attendees will explore the evolving landscape of FcRn inhibition, complement targeting, and B-cell modulation through expert-led presentations, panel discussions, and dedicated workshops.
Unlike pathway-specific or clinician-led events, this summit is indication-focused, mechanism-driven and tailored exclusively to drug developers, enabling deeper discussion on pathophysiology, differentiation and translational strategy.
Join your peers this July to de-risk development, identify new opportunities and gain a competitive edge in one of the fastest-moving areas of immunology and neurology.
URL - https://autoimmune-neuromuscular-drugdevelopment.com/?utm_source=immune-discovery&utm_medium=media-partner&utm_campaign=web-visitors&utm_content=companies-attending%2Fev-71061